PDCD1 and hepatocellular carcinoma: They evaluated 95 patients with advanced HCC and a baseline AFP of ≥10 ng/mL receiving anti-programmed cell death-1 (PD-1) antibodies (nivolumab or pembrolizumab), and identified a >10% AFP reduction after 4 weeks of treatment as an independent predictor of the best objective response (objective response rate, ORR 24.4%; odds ratio, OR: 7.259; p = 0.001) [35].